Skip to main content
. 2023 Mar 3;82(7):911–919. doi: 10.1136/ard-2022-223636

Figure 1.

Figure 1

Hazard ratios with 95% confidence intervals for the outcome all cancers other than non-melanoma skin cancer (overall, and by time since treatment start, number of previous b/tsDMARDs, in a CV enriched population, and using a 90-day latency period) in Swedish patients with RA starting treatment with a JAKi, a TNFi or non-TNFi bDMARD.